1. Pink Sheet

US FDA User Fee Conundrum: Collections Increase After 25% PDUFA Rate Hike

 
• By Derrick Gingery

With likely more fee-paying applications arriving at the agency, sponsors may be wondering whether user fees should have been increased as much as they were at the start of FY 2024.

revenue growth
The FDA raised its PDUFA revenue estimate $30m based on the pace of collections so far. • Source: Shutterstock

Despite efforts to make them predictable, user fee revenues continue to prove the opposite: sponsors may have been given an increase based on an expected downturn in submissions that is not materializing.

More than mid-way through fiscal year 2024, the US Food and Drug Administration increased its net collections estimate for the prescription drug user fee program by $30m, or about 2%, “because of the rate of collections thus far this fiscal year,” Funmi Ariyo, director of the user fees support staff in the FDA Office of Finance, Budget,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

More from Pathways & Standards

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.

Pink Sheet Podcast: Vaccine Review Political Interference, Missed Deadlines A Harbinger Of US FDA Problems?

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss FDA Commissioner Martin Makary’s decision to have one of his assistants lead negotiations for Novavax’s delayed COVID-19 vaccine review, as well as some recent missed review deadlines, which may be the result of recent FDA cuts.